View Single Post
Old 09-27-2016, 10:02 AM   #8
donocco
Senior Member
 
Join Date: Oct 2013
Posts: 474
Re: Aromatase Inhibitors: Personalized dosing?

That's a good point. Ill check what enzyme primarily metabolizes each of the three Aromatase Inhibitors and see if there are large diffefrences from ethnic group to ethnic group and or (more important) from person to person.

A good example of an ethic diffefrence is acetylation. The antibuberculosis drug, Isoniazid
is acetylated and Asians tend to be slow Acetylators. Asians are more likely to experience toxicity with Isoniazid.

A good example of person to person difference is the Enzyme Thiopurine Methyltransferase. This enzyme changes the anti-leukemic drug, 6 Mercaptopurine into its active form. Those children (we are talking about Acute Lymphoblastic Leukemia) with a more active Thiopurine Methyltransferase system need lower doses of the 6-Mercaptopurine. "Normal" doses in the active Thiopurine Methyltransferase children are too high and there is a greater chance of bone marrow toxicity. This enzyme is now routinely tested on all Leukemic children getting 6-mercaptopurine as maintenance therapy.

Paul
donocco is offline   Reply With Quote